Pharmaceutical compounding company Fagron (EBR:FAGR) plans to combine with Humco and its portfolio of drug-delivery technology in a deal valued up to $70 million, the companies announced today.
According to the agreement, Humco chairman & CEO Gregory Pulido will become executive chairman while Andrew Pulido, Humco’s president of global pharmaceuticals, will assume the role of president.
“I am pleased to welcome Humco to the Fagron Group. Their high-quality portfolio of branded pharmaceutical products and widely used patented delivery vehicles that are supplied to a broad customer base of pharmacy chains and wholesalers in the USA, is highly complementary to our extensive range of active pharmaceutical ingredients,” Fagron CEO Rafael Padilla said in prepared remarks.
“Humco is an excellent strategic fit for Fagron. By combining the two companies we create a strong competitive company with significant scale, strengthening our market position in the USA. Our global footprint and leading market positions in Europe and South-America will enable us to successfully launch and grow the innovative branded pharmaceutical products and delivery vehicles of Humco outside the USA. We look forward to welcoming the Humco employees to the Fagron family,” Padilla added.
“We are delighted and proud to become part of the Fagron Group. Being part of a large global organization and a world leader in pharmaceutical compounding, creates a more capable and dynamic company for our customers and employees. We complement each other, selling in adjacent markets with very little customer overlap, enabling a significant number of growth opportunities. While we introduce our successful and unique patented delivery vehicles and branded pharmaceutical products internationally, our customers can benefit from the excellent range of more than 1,600 high quality active pharmaceutical ingredients of Fagron,” Gregory said.
“The joint activities of Fagron and Humco are extremely well positioned to capitalize on growth opportunities in the USA and around the world,” Andrew added. “I am confident that our expertise, creativity and dedication will enable us to offer increased value to our customers, suppliers, and employees as well as to further extend Fagron’s leadership in the market for personalized medication.”
Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.